Arpana Rayannavar1, Okan U Elci2,3, Lauren Mitteer1, Diva D De León4,5. 1. Division of Endocrinology and Diabetes, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. 2. Westat, Rockville, Maryland, USA. 3. Biostatistics and Data Management Core, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. 4. Division of Endocrinology and Diabetes, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA, deleon@email.chop.edu. 5. Department of Pediatrics,Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA, deleon@email.chop.edu.
Abstract
BACKGROUND: Effective treatment and close monitoring in children with congenital hyperinsulinism (HI) are important to prevent hypoglycemic-associated brain damage. The current monitoring approach involves measuring plasma glucose intermittently, but this does not provide a comprehensive assessment of glycemic control and may fail to detect episodes of hypoglycemia. OBJECTIVE: To determine whether Dexcom G5®, a continuous glucose monitoring system (CGMS), is an accurate and effective method for monitoring glycemic control in children with HI. METHODS: Cross-sectional, observational study in 15 children with HI. Participants wore a blinded Dexcom G5® device for 2 weeks. At the end of 2 weeks, data from the Dexcom G5® and home glucose meter were downloaded and analyzed. RESULTS: Fourteen children (15-67 months) completed the study. Using Bland-Altman analysis, the mean (SD) difference between 1,155 paired CGM and glucose meter readings was -8.09 (53.76). The sensitivity and specificity of CGM to detect hypoglycemia (<70 mg/dL) were 86 and 81.4%, respectively. The positive predictive values for hypoglycemia and severe hypoglycemia (<54 mg/dL) detected by CGM were low (50.3 and 14.8%, respectively), while the negative predictive values were high (96.4% for glucose <70 mg/dL and 99.1% for glucose <54 mg/dL). CONCLUSION: Our study showed that CGM is not a reliable method to monitor for hypoglycemia, given the high number of false positive hypoglycemia readings. However, CGM can be useful in preventing unnecessary checks by glucose meter during times of normoglycemia. Therefore, the benefits of using CGM in patients with HI would be in guiding the need to check plasma glucose by glucose meter rather than point accuracy.
BACKGROUND: Effective treatment and close monitoring in children with congenital hyperinsulinism (HI) are important to prevent hypoglycemic-associated brain damage. The current monitoring approach involves measuring plasma glucose intermittently, but this does not provide a comprehensive assessment of glycemic control and may fail to detect episodes of hypoglycemia. OBJECTIVE: To determine whether Dexcom G5®, a continuous glucose monitoring system (CGMS), is an accurate and effective method for monitoring glycemic control in children with HI. METHODS: Cross-sectional, observational study in 15 children with HI. Participants wore a blinded Dexcom G5® device for 2 weeks. At the end of 2 weeks, data from the Dexcom G5® and home glucose meter were downloaded and analyzed. RESULTS: Fourteen children (15-67 months) completed the study. Using Bland-Altman analysis, the mean (SD) difference between 1,155 paired CGM and glucose meter readings was -8.09 (53.76). The sensitivity and specificity of CGM to detect hypoglycemia (<70 mg/dL) were 86 and 81.4%, respectively. The positive predictive values for hypoglycemia and severe hypoglycemia (<54 mg/dL) detected by CGM were low (50.3 and 14.8%, respectively), while the negative predictive values were high (96.4% for glucose <70 mg/dL and 99.1% for glucose <54 mg/dL). CONCLUSION: Our study showed that CGM is not a reliable method to monitor for hypoglycemia, given the high number of false positive hypoglycemia readings. However, CGM can be useful in preventing unnecessary checks by glucose meter during times of normoglycemia. Therefore, the benefits of using CGM in patients with HI would be in guiding the need to check plasma glucose by glucose meter rather than point accuracy.
Authors: F Boscari; S Galasso; G Acciaroli; A Facchinetti; M C Marescotti; A Avogaro; D Bruttomesso Journal: Nutr Metab Cardiovasc Dis Date: 2018-01-31 Impact factor: 4.222
Authors: Katherine Lord; Jerilynn Radcliffe; Paul R Gallagher; N Scott Adzick; Charles A Stanley; Diva D De León Journal: J Clin Endocrinol Metab Date: 2015-09-01 Impact factor: 5.958
Authors: K Mazor-Aronovitch; D Gillis; D Lobel; H J Hirsch; O Pinhas-Hamiel; D Modan-Moses; B Glaser; H Landau Journal: Eur J Endocrinol Date: 2007-10 Impact factor: 6.664
Authors: Liisa Muukkonen; Jonna Männistö; Jarmo Jääskeläinen; Riitta Hannonen; Hanna Huopio Journal: Dev Med Child Neurol Date: 2018-09-23 Impact factor: 5.449
Authors: Bruce A Buckingham; Dan Raghinaru; Fraser Cameron; B Wayne Bequette; H Peter Chase; David M Maahs; Robert Slover; R Paul Wadwa; Darrell M Wilson; Trang Ly; Tandy Aye; Irene Hramiak; Cheril Clarson; Robert Stein; Patricia H Gallego; John Lum; Judy Sibayan; Craig Kollman; Roy W Beck Journal: Diabetes Care Date: 2015-06-06 Impact factor: 19.112
Authors: Julie Raskin; Tai L S Pasquini; Sheila Bose; Dina Tallis; Jennifer Schmitt Journal: Front Endocrinol (Lausanne) Date: 2022-04-28 Impact factor: 6.055
Authors: Chris Worth; Yesica Tropeano; Pon Ramya Gokul; Karen E Cosgrove; Maria Salomon-Estebanez; Senthil Senniappan; Antonia Dastamani; Indraneel Banerjee Journal: BMJ Open Diabetes Res Care Date: 2022-06
Authors: Katja A Schönenberger; Luca Cossu; Francesco Prendin; Giacomo Cappon; Jing Wu; Klaus L Fuchs; Simon Mayer; David Herzig; Andrea Facchinetti; Lia Bally Journal: Front Nutr Date: 2022-04-07
Authors: Indraneel Banerjee; Julie Raskin; Jean-Baptiste Arnoux; Diva D De Leon; Stuart A Weinzimer; Mette Hammer; David M Kendall; Paul S Thornton Journal: Orphanet J Rare Dis Date: 2022-02-19 Impact factor: 4.123
Authors: Santhi N Logel; Ellen L Connor; David A Hsu; Rachel J Fenske; Neil J Paloian; Darryl C De Vivo Journal: Ann Clin Transl Neurol Date: 2021-10-06 Impact factor: 4.511
Authors: Sameera Hannah Auckburally; Chris Worth; Maria Salomon-Estebanez; Jacqueline Nicholson; Simon Harper; Paul W Nutter; Indraneel Banerjee Journal: Front Endocrinol (Lausanne) Date: 2022-07-19 Impact factor: 6.055